VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY Russian patent published in 2013 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: there are presented methods for prediction of a higher risk of hypertension related to the VEGF antagonist therapy in a patient. What is involves is screening of a sample recovered from the patient for the purpose of VEGF (-1498C/T) and VEGF (-634G/C) genome polymorphisms. If the genotype comprises the VEGF (-1498C) and/or VEGF (-634G) polymorphisms, the patient is likely to have a higher risk of hypertension related to the VEGF antagonist therapy. What is presented is a kit for prediction of a higher risk of hypertension in the patient, related to the VEGF antagonist therapy, comprising a first oligonucleotide and a second oligonucleotide specific for polymorphism in the VEGF gene selected from the group consisting of VEGF (-1498C/T) and VEGF (-634G/C).

EFFECT: effective methods and kits for prediction of a higher risk of hypertension related to the VEGF antagonist therapy in the patient.

12 cl, 5 tbl, 1 ex